Martin Sebastian
Overview
Explore the profile of Martin Sebastian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
4302
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kasper S, Sebastian M
Dtsch Arztebl Int
. 2025 Feb;
(Forthcoming).
PMID: 40009739
Background: Mutations of the KRAS oncogene are found in up to 20% of all cancers, and particularly in non-small-cell lung cancer (NSCLC) (20-40%) and colorectal cancer (CRC) (30-50%). Inhibitors of...
2.
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
3.
Acker F, Reck M, Martin D, Rieken S, Heinzen S, Rost M, et al.
Eur J Cancer
. 2025 Feb;
218:115266.
PMID: 39893747
Background: In patients with unresectable, stage III non-small cell lung cancer (NSCLC), durvalumab maintenance after concurrent chemoradiotherapy (cCRT) was shown to improve survival over placebo. As subgroup analyses indicated better...
4.
Acker F, Sebastian M
Transl Lung Cancer Res
. 2025 Jan;
13(12):3831-3834.
PMID: 39830755
No abstract available.
5.
Yeoh J, Hamilton G, Dinh D, Brennan A, Reid C, Stub D, et al.
Cardiovasc Revasc Med
. 2024 Nov;
PMID: 39532593
Background: Complex Revascularisation in High-Risk Indicated Patients (CHIP) is emerging in Percutaneous Coronary Intervention (PCI). We document the frequency and outcomes following CHIP PCI in the Australian population, to understand...
6.
Planchard D, Wolf J, Solomon B, Sebastian M, Wermke M, Heist R, et al.
Lung Cancer
. 2024 Oct;
197:107964.
PMID: 39383771
Background: Genetic alterations activating the MAPK pathway are common in non-small cell lung cancer (NSCLC). Patients with NSCLC may benefit from treatment with the pan-RAF inhibitor naporafenib (LXH254) plus the...
7.
Acker F, Klein A, Rasokat A, Eisert A, Kron A, Christopoulos P, et al.
Clin Lung Cancer
. 2024 Aug;
25(8):672-682.e5.
PMID: 39153867
Purpose: MET amplification is a common resistance mechanism to EGFR inhibition in EGFR-mutant non-small cell lung cancer (NSCLC). Several trials showed encouraging results with combined EGFR and MET inhibition (EGFRi/METi)....
8.
Gray J, Markovets A, Reungwetwattana T, Majem M, Nogami N, Peled N, et al.
J Thorac Oncol
. 2024 Jul;
19(11):1525-1538.
PMID: 39029876
Introduction: EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and...
9.
Acker F, Chromik J, Tiedjen E, Wolf S, Vischedyk J, Makowka P, et al.
Eur J Haematol
. 2024 Jul;
113(5):623-630.
PMID: 39023132
Background: First-line treatment in patients with acute myeloid leukemia (AML) unfit for intensive therapy is the combination of a hypomethylating agent (HMA) with venetoclax (VEN). However, retrospective data confirming the...
10.
Eberhardt W, Sebastian M
J Thorac Oncol
. 2024 Jun;
19(6):849-851.
PMID: 38849162
No abstract available.